淩雲半導體 CRUS 深 滬
已收盤 09-19 16:00:00 美东时间
120.12
-2.630
-2.14%
華盛通- 最 高122.22
- 今 開122.22
- 成交量 167.57万股
- 最 低 118.32
- 昨 收 122.75
- 總市值 61.62亿
- 52周最高 126.04
- 市盈率 靜 20.02
- 換手率 3.27%
- 52周最低 75.83
- 委 比 72.51%
- 總股本 5129.84万
- 歷史最高 147.46
- 量 比 3.29
- 振 幅 3.18%
- 歷史最低 12.52
- 每 手 1
- 風險率 8.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
Corbus Pharmaceuticals Holdings, Inc. announced the U.S. FDA granted Fast Track designation for CRB-701 to treat recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and anti-PD(L)-1 therapy. CRB-701, a next-generation antibody drug conjugate targeting Nectin-4, has already received Fast Track designation for relapsed or refractory metastatic cervical cancer in December 2024. The company will present...
09-16 12:00
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
对美模拟芯片反倾销调查，国产替代加速，相关核心标的梳理
（来源：金融小博士） 9月13日，我国商务部公告对原产于美国4家生产商（德州仪器、ADI、博通、安森美）的进口相关模拟芯片发起反倾销立案调查。 根据相关媒体...
09-14 17:48
Stifel Maintains Buy on Cirrus Logic, Raises Price Target to $130
Stifel analyst Tore Svanberg maintains Cirrus Logic (NASDAQ:CRUS) with a Buy and raises the price target from $120 to $130.
09-12 22:18
格罗方德：美国政府没要股权
：内容编译自路透。 在美国政府收购芯片制造商英特尔 10% 的股权几天后，格芯周三表示，其《芯片法案》资金“完好无损”，且该框架不涉及任何类型的股权。 该公司财...
08-28 09:11
QuickLogic Appoints Ron Shelton to Board of Directors
SAN JOSE, Calif., Aug. 13, 2025 /PRNewswire/ -- QuickLogic Corporation (NASDAQ: QUIK), a leading developer of embedded FPGA (eFPGA) Hard IP and User Tools, ruggedized FPGAs, and Endpoint AI/...
08-13 19:33
Cirrus Logic shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance above estimates.
Cirrus Logic shares are trading higher after the company reported better-than-e...
08-06 04:39
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
Corbus Pharmaceuticals has initiated the multiple ascending dose (MAD) portion of its Phase 1 trial for CRB-913, a peripherally restricted CB1 inverse agonist for obesity treatment. The MAD study, scheduled to complete in Q3 2025, follows the single ascending dose (SAD) study, which showed no treatment-related neuropsychiatric events. The company plans to launch a Phase 1b dose-range finding study in obese individuals later this year. CRB-913 is ...
06-30 12:00
